Elevated Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio after First Cycle of Chemotherapy and Better Survival in Esophageal Cancer Patients Receiving Concurrent Chemoradiotherapy.

Tseng, Ruo-Han; Lai, Kuan-Ming; Tsai, Chien-Yu; Yan, Sheng-Lei

Tseng, Ruo-Han; Lai, Kuan-Ming; Tsai, Chien-Yu; Yan, Sheng-Lei.

Afiliação

Tseng RH; Division of Hematology and Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan.
Lai KM; Division of Hematology and Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan.
Tsai CY; Division of Hematology and Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua 500, Taiwan.
Yan SL; Division of Gastroenterology, Department of Internal Medicine, Chang-Bing Show Chwan Memorial Hospital, Changhua 505, Taiwan.

Curr Oncol ; 29(11): 8825-8834, 2022 11 17.

Article em En | MEDLINE | ID: mdl-36421347

Assuntos

Neoplasias Esofágicas; Carcinoma de Células Escamosas do Esôfago; Humanos; Neutrófilos/patologia; Neoplasias Esofágicas/tratamento farmacológico; Neoplasias Esofágicas/patologia; Estudos Retrospectivos; Cisplatino/uso terapêutico; Prognóstico; Carcinoma de Células Escamosas do Esôfago/terapia; Linfócitos/patologia; Quimiorradioterapia

Palavras-chave

concurrent chemoradiotherapy; esophageal cancer; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; survival

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Carcinoma de Células Escamosas do Esôfago Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Curr Oncol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google